Jinushi Masahisa, Takehara Tetsuo, Tatsumi Tomohide, Hiramatsu Naoki, Sakamori Ryotaro, Yamaguchi Shinjiro, Hayashi Norio
Department of Molecular Therapeutics, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan.
J Hepatol. 2005 Dec;43(6):1013-20. doi: 10.1016/j.jhep.2005.05.026. Epub 2005 Jun 29.
BACKGROUND/AIMS: MHC class I-related chain A (MICA), a human ligand of natural killer (NK) cell stimulatory receptor NKG2D, is expressed in human hepatocellular carcinomas (HCC). Earlier research demonstrated that the soluble form of MICA (sMICA) is released from some types of tumors, but its presence and role in HCC was not determined.
Serum sMICA was studied in 26 patients with HCC. In vitro experiments were performed to examine the impact of sMICA on NK cell expression of NKG2D and subsequent dendritic cell (DC) activation.
The levels of sMICA were frequently elevated in patients with advanced HCC. The elevation of sMICA was associated with down-regulated NKG2D expression and impaired activation of NK cells. In vitro experiments revealed that sMICA derived from advanced HCC was responsible for down-modulation of NKG2D expression and NK cell functions. NK cells upon stimulation of human hepatoma cells induced maturation of DC and enhanced the allostimulatory capacity of DC; maturation and activation of DC were completely abolished when NK cells were pre-treated with sMICA-containing serum.
sMICA is present in sera of patients with advanced HCC and may serve as a tumor evasion mechanism by negatively modulating both innate and adaptive immunity.
背景/目的:MHC I类相关链A(MICA)是自然杀伤(NK)细胞刺激受体NKG2D的人类配体,在人类肝细胞癌(HCC)中表达。早期研究表明,MICA的可溶性形式(sMICA)可从某些类型的肿瘤中释放出来,但尚未确定其在HCC中的存在情况和作用。
对26例HCC患者的血清sMICA进行了研究。进行体外实验以检测sMICA对NK细胞NKG2D表达及随后树突状细胞(DC)激活的影响。
晚期HCC患者的sMICA水平经常升高。sMICA的升高与NKG2D表达下调和NK细胞激活受损有关。体外实验表明,晚期HCC来源的sMICA可导致NKG2D表达下调和NK细胞功能受损。人肝癌细胞刺激后的NK细胞可诱导DC成熟并增强DC的同种异体刺激能力;当用含sMICA的血清预处理NK细胞时,DC的成熟和激活完全被消除。
sMICA存在于晚期HCC患者的血清中,可能通过对固有免疫和适应性免疫的负调节作用作为一种肿瘤逃逸机制。